¥ Nonstandard abbreviations: CA, carbonic anhydrase; AZA, acetazolamide; TPM, topiramate; SAR, structure-activity relationship; SPR, structure-property relationship; HIF, hypoxia-inducible factor; P e , apparent in vitro effective permeability 2 Abstract. The contribution of membrane-bound carbonic anhydrases (CAs) to hypoxic tumour growth and progression in cancer implicates cancer-associated CAs as a promising drug target for oncology. In this paper we present a new class of sulfonamide-linked neoglycoconjugate that was designed to selectively target and inhibit the extracellular domains of the cancer-relevant CA isozymes. We describe the application of novel, yet straightforward, chemistry towards the synthesis of inhibitors that comprise both S-glycosyl sulfenamides and S-glycosyl sulfonamides. We also present the CA inhibition profile of our new neoglycoconjugates, more specifically a library of 30 compounds (3-32) that were designed to optimize both SAR (structure-activity relationship) and SPR (structure-property relationship) characteristics. We show that our approach produces neutral, water soluble and potent inhibitors (K i s in the low nanomolar range) that target cancer-associated CAs.
Introduction
In solid tumours vasculature is poor; this limits blood supply to the tumour mass and in turn reduces delivery of O 2 to the tumour cells. At a molecular level, low O 2 , known as hypoxia (≡ 0.1-5% O 2 ), induces the activation of a transcription factor, appropriately named hypoxia-inducible factor (HIF). 1 High levels of HIF regulate a signalling cascade, involving ~hundred genes, that adapt cellular functions to allow solid tumour cells to not only survive hypoxia, but to proliferate and metastasize. 1 Carbonic anhydrase IX (CA IX) is one of the most highly induced HIF responsive genes and is overexpressed and sustained in a number of solid tumours including breast, brain (glioblastoma), clear cell renal, colorectal, head and neck, bladder and non-small cell lung carcinomas. [2] [3] [4] CA IX is a multidomain protein consisting of an N-terminal proteoglycan like domain, a transmembrane domain, a short intracellular domain and an extracellular catalytic domain. 5 The catalytic domain of CAs contains an active site Zn 2+ . This metal cation is a strong Lewis acid that binds to and activates a substrate H 2 O molecule, to catalyze the reversible reaction: CO 2 + H 2 O  HCO 3 -+ H + . 6 The hydration of CO 2 does not proceed at an appreciable rate under physiological conditions in the absence of CA enzymes. 6 Tumour cells also experience elevated metabolism and acid production compared to normal cells. 7, 8 If this acid-load is allowed to accumulate then intracellular pH (pH i ) would fall to dangerously low levels and disrupt critical biological functions. 7, 8 To counter this, tumour cells have evolved a mechanism to extrude acid into the extracellular environment. Recent evidence has demonstrated that it is cellgenerated CO 2 that is primarily responsible for the rapid removal of acid equivalents from tumour cells, and not lactic acid which has been the popular belief until now. 7, 8 Cell-derived CO 2 is freely membrane permeable, so provided there is sufficient outward gradient this CO 2 diffuses to the extracellular space, where in poorly vascularized hypoxic tumour regions, it is hydrated to bicarbonate (HCO 3 -) and a proton (H + ): CO 2 + H 2 O  HCO 3 -+ H + . The net effect is to trap acid extracellularly to lower extracellular pH (pH e ~6.9-7.0) and maintain pH i (~7.2) with HCO 3 -recycled back into the cell, where it combines with a proton to give CO 2 (catalyzed by intracellular CA II) to continue this cycle, Figure 1 . 8 The contribution of CA IX (and CA XII -which is also HIF activated) to hypoxic tumour growth and progression has long been debated, however the intensity of recent research has provided convergent evidence that affirms that these transmembrane CAs, with their extracellular oriented active sites, are the key molecules for regulating cancer cell pH i during hypoxia and thus are major tumour prosurvival enzymes. 7, 8 Very recently, it was reported that 'knockout' of CA IX and CA XII using gene silencing technology led to a remarkable 85% tumour growth retardation in colorectal cancer xenograft modelsthis research has advanced our understanding of the pivotal role of CAs in cancer and implicates cancerassociated CAs as a new and promising drug target for oncology therapies. 7 Of the 12 catalytically active CAs known, only the membrane bound CA IX and CA XII isozymes are associated with cancer. CA IX is a transmembrane enzyme with an extracellular oriented active site domain.
The CA-mediated pH i regulation of hypoxic tumour cells underpins a compelling case for the development of small-molecule CA inhibitors as chemical probes and as lead molecules to appraise the potential of cancer-associated CA IX and XII for therapeutic intervention. In the last few years our group has established a novel approach to targeting CA IX and XII with small molecule inhibitors. 
Carbonic Anhydrase Inhibition
The enzyme inhibition characteristics for the 30 new glycoconjugates 3-32 were determined by assaying the CA catalyzed hydration of CO 2 , Table 1 . 27 Isozyme selectivity ratios for 3-32 are in Table   2 . Reference data for clinically used CA inhibitors acetazolamide (AZA) and topiramate (TPM) as well as for aminosulfonamide precursors 1 and 2 are included for comparison with the new glycoconjugates reported in this study. and good CA II and XII inhibitors (low nanomolar K i s). We do however observe variation at CA IX, with the K i s for this selection of inhibitors ranging from low nM to micromolar. The observed trends demonstrate that the compounds of this study are consistent with our premise regarding the active site tolerance of CAs to variable inhibitor structures, although interestingly have allowed us to identify that the cancer-associated CA IX isozyme is the least tolerant to structural changes. This observation should prove a useful aid in defining the opportunities for future medicinal chemistry efforts to selectively target this important tumour-associated CA isozyme with drug-like small molecule inhibitors. Table 3 . Inhibition data for hCA isozymes I, II, IX and XII with selected glucoconjugate CA inhibitors (33a-37a, 33b-37b) and compounds 8 and 13 of the present study. Figure 2 . Structures of glucoconjugate CA inhibitors (33a-37a R = AC, 33b-37b R = Ac). Passive membrane permeability. The physical barrier of the cell membrane is not a contributing factor in CA inhibition studies that utilize pure recombinant enzymes, however in the development of compounds that target hCA IX and XII in vivo the passive diffusion across biological membrane barriers is likely to be central. In general, passive diffusion across a biological membrane correlates very well with the lipophilicity of the small molecule, with membrane permeability generally decreasing with increasing small molecule polarity or with capacity for hydrogen bonding. Our strategy to target the extracellular catalytic domain of cancer-associated CAs is to deliberately manipulate physicochemical properties of the inhibitor so as to impart membrane impermeability. Log P represents intrinsic lipophilicity and compounds with Log P < 0 typically have good solubility but poor lipid bilayer permeability (although paracellular permeability may be a contributor for very small hydrophilic molecules). 29,30a values of compounds generated from 1 and 2 differ in magnitude by 0.29, with scaffold 2 more hydrophobic (higher Log P) than 1 owing to one additional methylene group. The Log P trend is acetylated sulfenamides > acetylated sulfonamides > free sugar sulfonamides. This is consistent with (i) the incorporated acetate groups increasing the lipophilicity, and (ii) the sulfonamide oxygens increasing the polarity of the glycoconjugates. The calculated Log P values for the acetylated sulfonamides range from -1.11 to -1.85, while the more hydrophilic free sugar sulfonamides have log P values that range from -2.56 to -4.94. All sulfonamides have Log P values that fall within the range indicative of molecules with poor membrane permeability, i.e. Log P < 0.
Permeability measurements through artificial lipid membrane biolayers have been extensively used to classify small molecules for their passive membrane permeability characteristics. [31] [32] [33] We have previously used this technique to measure the apparent in vitro effective permeability (P e ) of anomeric sulfonamides. 10 Typical P e values for high permeability compounds are > 3 × 10 -6 cm s -1 while for low permeability compounds are < 3 × 10 -6 cm s -1.34, 35 The P e of per-O-acetylated glucoconjugate (8), fully deprotected glucoconjugate (13) , AZA and control compounds were determined using a parallel artificial membrane permeability assay (PAMPA) [31] [32] [33] as previously described. 10 The experimental values of P e at pH 7.4 using the PAMPA assay are included in In order to ensure that the intrinsically low permeability characteristics of the CA inhibitors is unlikely to limit bioavailability for compounds that may progress to animal studies we envisage either intravenous administration (the free sugars have good aqueous solubility) or for oral delivery a prodrug strategy that utilizes ester groups on the sugar hydroxyls to improve intestinal absorption, with ester hydrolysis to follow absorption.
Experimental Section
Chemistry. 
General Procedure 1
To a solution of per-O-acetylated derivative (1.0 equiv.) in acetonitrile was added thiourea (1.3 equiv.) and boron trifluoride diethyl etherate (2.1 equiv.). The reaction mixture was refluxed until starting material was consumed (~ 30 min) then let cool to room temperature (rt). Acetic anhydride (2.5 equiv.) and triethylamine (4.5 equiv.) were added and the solution stirred at rt overnight in the absence of light.
The reaction mixture was concentrated and the residue diluted in dichloromethane (CH 2 Cl 2 ) before washing with aqueous 5 % HCl (× 1) and brine (× 2). The aqueous extracts were combined and back extracted with CH 2 Cl 2 (× 2). The organic extracts were combined, dried over MgSO 4 , filtered and evaporated.
2,3,4,6-tetra-O-acetyl-1-S-acetyl-1-thio-β-D-glucopyranose (a)
Thioacetate a was prepared from per-O-acetylated D-glucose using General Procedure 1.
Recrystallization from ethanol afforded off-white crystals (77 % yield). R f = 0.67 (1:1 EtOAc/hexane). 
2,3,4,6-tetra-O-acetyl-1-S-acetyl-1-thio-β-D-galactopyranose (b)
Thioacetate b was prepared from per-O-acetylated D-galactose using General Procedure 1.
Recrystallization from ethanol afforded off-white crystals (75 % yield). R f = 0.67 (1:1 EtOAc/hexane). 1H, H-3), 4. 
Methyl 2,3,4-tetra-O-acetyl-1-S-acetyl-1-thio-β-D-glucopyranuronate (c)
Thioacetate c 
2,2',3,3',4',6,6'-Hepta-O-acetyl-1-S-acetyl-1-thio-β-lactose (d)
Thioacetate d 
2,2',3,3',4',6,6'-Hepta-O-acetyl-1-S-acetyl-1-thio-β-maltose (e)
The title compound was prepared from per-O-acetylated maltose using General Procedure 1.
Recrystallization from methanol afforded off-white crystals (68 % yield). R f = 0.48 (1:1 EtOAc/hexane). 
Synthesis of sulfenamides 3-7 and 18-22 -General Procedure 2
A solution of thioacetate (a-e, 1.0 equiv.) under nitrogen was prepared in anhydrous methanol.
Diethylbromomalonate ( 
N-4-(aminosulfonyl)benzyl-S-(2,3,4,6-tetra-O-acetyl-1-thio-β-D-galactopyranosyl)sulfenamide (4)
Sulfenamide 4 87.5 (C-1), 76.3 (C-4), 75.9 (C-5), 73.7 (C-3), 70.6 (C-3'), 70.0 (C-5'), 69.2 (C-2), 68.1 (C-2'), 67.3 (C-4'), 62.7 (C-6), 61.1 (C-6'), 55. [ 73.6 (C-3), 70.5 (C-3'), 69.9 (C-5'), 69.1 (C-2'), 68.0 (C-2), 67.2 (C-4'), 62.6 (C-6'), 61.0 (C-6), 54. 73.6 (C-4), 69.4 (C-2'), 68.8 (C-3'), 68.2 (C-2), 68.0 (C-5), 67.8 (C-4'), 63.0 (C-6'), 61. 
Methyl N-4-(aminosulfonyl)benzyl-S-(2,3,4-tri-O-acetyl-1-thio-β-D-

glucopyranuronoyl)sulfenamide (5)
α] 25 D = -102 (c = 1.2, chloroform). 1 H NMR (500 MHz, DMSO-d 6 ): δ = 7.72 (d, J = 8.0 Hz, 2H
N-4-(aminosulfonyl)phenethyl-S-(2,2',3,3',4',6,6'-hepta-O-acetyl-1-thio-β-maltosyl)sulfenamide
Oxidation of sulfenamide derivatives -General procedure 3
The sulfenamide derivative (1.0 equiv.) was solubilized in CH 2 Cl 2 . Meta-chloroperoxybenzoic acid ( 
N-4-(aminosulfonyl)benzyl-S-(2,3,4,6-tetra-O-acetyl-1-thio-β-D-glucopyranosyl)sulfonamide (8)
Sulfonamide 8 (C-1), 74.6 (C-5), 72.8 (C-3), 67.6, 67.5 (C-4, C-2), 61.6 (C-6), 46. 
N-4-(aminosulfonyl)benzyl-S-(2,3,4,6-tetra-O-acetyl-1-thio-β-D-galactopyranosyl)sulfonamide (9)
Sulfonamide 9 
N-4-(aminosulfonyl)benzyl-S-
N-4-(aminosulfonyl)phenethyl-S-(1-thio-β-maltosyl)sulfonamide (30)
Sulfonamide 30 was prepared from sulfonamide 25 according to the General Procedure 4. The expected derivative was obtained after freeze-drying as a yellow gum (60 % yield). R f = 0.12 (9:1 CH 3 CN/H 2 O).
[α] 
Carbonic anhydrase inhibition assay
An SX.18MV-R Applied Photophysics stopped-flow instrument was used for assaying the CA I, II, and IX CO 2 hydration activity. 27 Phenol red (at a concentration of 0.2 mM) was used as indicator, working at the absorbance maximum of 557 nm, with 10 mM Hepes (pH 7.5) as buffer, 0.1 M NaClO 4 (for maintaining constant the ionic strength-this anion is not inhibitory), following the CA-catalyzed CO 2 hydration reaction for a period of 10 -100 s. Saturated CO 2 solutions in water at 20 ºC were used as substrate. Stock solutions of inhibitors were prepared at a concentration of 10 -50 mM (in the assay buffer) and dilutions up to 1 nM performed with the assay buffer mentioned above. Inhibitor and enzyme solutions were preincubated together for 15 min at room temperature prior to assay, in order to allow for the formation of the E-I complex. The inhibition constants were obtained by non-linear least-squares methods using PRISM 3. The curve-fitting algorithm allowed us to obtain the IC 50 values, working at the lowest concentration of substrate of 1.7 mM), from which K i values were calculated by using the Cheng-Prusoff equation. The catalytic activity (in the absence of inhibitors) of these enzymes was calculated from Lineweaver-Burk plots and represent the mean from at least three different determinations. Enzyme concentrations were 10 nM for CA I and CA II, 14 nM for CA IX and 0.11 µM for hCA XII Kinetic parameters and inhibition constants were calculated as described previously. 37, 38 Enzymes used here were recombinant ones, prepared and purified as described earlier.
37,38
Conclusions
Recent experimental evidence has implicated CAs as a drug target with promising potential for the development of much needed personalized cancer therapies targeting hard-to-treat hypoxic tumours.
Here we have developed a novel and straightforward method for the stereoselective synthesis of small molecule sulfonamide-linked neoglycoconjugates. In these compounds the carbohydrate fragment is Finally, our results also showcase new chemistry towards S-glycosyl secondary sulfonamides. This chemistry is straightforward and synthetically tractable, needing only a primary amine functional group in the molecule of interest and a S-glycosyl acetate partner. We believe this chemistry may readily be applied towards the synthesis of diverse range of therapeutically relevant neoglycoconjugates and thus will have significant impact across broad areas of medicinal chemistry and chemistry. 
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